Cherry-red spot

A classic funduscopic finding: a bright red fovea standing out against a pale, opaque macula. The pallor comes from storage material accumulating in the retinal ganglion cells that surround the macula; the fovea has no ganglion cells, so the underlying choroidal red shows through unchanged. The contrast creates the "cherry-red" appearance. The finding is highly specific: when present, the differential is short, distinctive, and overwhelmingly lysosomal storage disease (LSD).

Cherry-red spot is a bedside accelerator: an ophthalmology finding that collapses a wide neurodegenerative differential to a handful of LSDs in minutes. Two clinical pairings dominate:

1. Cherry-red spot + neurologic regression + NO organomegaly → GM2 gangliosidosis (Tay-Sachs).
2. Cherry-red spot + neurologic regression + hepatosplenomegaly → GM1, Niemann-Pick A, Sandhoff, sialidosis type 2.

After that split, ethnicity (Ashkenazi Jewish founder for Tay-Sachs, Niemann-Pick A), the presence of exaggerated startle response, dysmorphism / coarsening, and age of onset narrow further.

GM2 gangliosidoses

• Tay-Sachs disease (HEXA, AR): the prototypical cherry-red spot disease. Infant develops at 3-6 months with exaggerated startle response to noise, progressive weakness, loss of milestones, macrocephaly (from storage), seizures, blindness, death by age 4. No hepatosplenomegaly (this is the key clinical splitter from Niemann-Pick A and GM1). Ashkenazi Jewish founder mutations (carrier frequency ~1 in 27 AJ); also French-Canadian and Pennsylvania-Dutch founders. Enzyme: hexosaminidase A activity (low). Late-onset variants in adolescents and adults present with motor neuron disease, ataxia, and psychiatric features without the classic cherry-red.
• Sandhoff disease (GM2 gangliosidoses, HEXB, AR): similar infantile presentation to Tay-Sachs but with hepatosplenomegaly and bony changes (dysostosis multiplex). No founder population; deficient hexosaminidase A AND B activity.

GM1 gangliosidosis (GLB1, AR)

• Infantile form: coarse facies + hepatosplenomegaly + dysostosis multiplex + cherry-red spot + severe neurodegeneration. Can look Hurler-like clinically, but Hurler does not have cherry-red. Juvenile and adult forms present later, with dystonia and skeletal findings rather than the classical infantile picture.
• Enzyme: beta-galactosidase (low). Same enzyme is deficient in Morquio B (without the storage / dysostosis pattern).

Sialidoses

• Sialidosis type 1 ("cherry-red spot myoclonus syndrome", NEU1, AR): adolescent or young adult with progressive myoclonus + ataxia + cherry-red spot but normal intellect. No somatic / dysmorphic features. Urine bound sialic acid elevated.
• Sialidosis type 2: more severe, earlier onset, with somatic features (dysmorphism, hepatosplenomegaly, dysostosis) plus the cherry-red.

Sphingomyelin storage

• Niemann-Pick disease type A (SMPD1, AR): infantile-onset, hepatosplenomegaly + cherry-red + profound neurodegeneration. Ashkenazi Jewish founder. Death usually before age 3. Enzyme: acid sphingomyelinase (low). Type B (also SMPD1) has visceral disease without the severe neurologic phenotype and no cherry-red.

Galactosialidosis

• CTSA (cathepsin A): combined deficiency of beta-galactosidase and neuraminidase. Coarse features + cherry-red + dysostosis + neurologic involvement. Often confused with GM1 or sialidosis on presentation.

Less classic but reported

• Krabbe disease: occasionally cited but not a typical finding.
• Multiple sulfatase deficiency, Farber disease (severe forms): rare reports.

1. Dilated funduscopic examination by ophthalmology, with photographs documenting the finding (parents can take time to accept the diagnosis; the photograph helps).
2. Lysosomal enzyme panel (leukocyte-based): hexosaminidase A and B (Tay-Sachs vs Sandhoff), beta-galactosidase (GM1), acid sphingomyelinase (Niemann-Pick A/B), neuraminidase (sialidosis; activity assay is tricky and not all labs offer it).
3. Urine oligosaccharides and bound sialic acid: abnormal pattern in sialidoses, galactosialidosis, GM1.
4. CMA + targeted gene confirmation: HEXA, HEXB, GLB1, SMPD1, NEU1, CTSA. For Tay-Sachs in Ashkenazi families, founder mutation panel is the cheapest first test; sequence the gene if negative.
5. Brain MRI: thalami often appear bright on T1 (storage material), basal ganglia abnormalities, progressive cerebral atrophy.
6. Skeletal survey if Hurler-like features suggest dysostosis multiplex (GM1, Sandhoff, sialidosis type 2, galactosialidosis).
7. Carrier screening and reproductive counseling for the family once the diagnosis is established. Ashkenazi Jewish couples should be offered expanded carrier screening that includes HEXA, SMPD1 (and others) before subsequent pregnancies.